XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.22.2

Collaboration and Other Agreements - Incyte Corporation (Details) | 3 Months Ended | 6 Months Ended | 7 Months Ended | 9 Months Ended | 24 Months Ended | 54 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jul. 31, 2022 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2018 USD ($) | Dec. 31, 2018 USD ($) performanceObligation | Jun. 30, 2022 USD ($) | Jul. 01, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | $ 26,007,000 |  | $ 30,757,000 | $ 37,108,000 | $ 47,638,000 |  |  |  |  |  |  |  |
Deferred revenue, current | 11,565,000 |  |  | 11,565,000 |  |  |  |  |  | $ 11,565,000 |  | $ 20,646,000 |
Deferred revenue, net of current portion | 6,163,000 |  |  | 6,163,000 |  |  |  |  |  | 6,163,000 |  | 0 |
Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |
Potential development and regulatory milestone payments under agreement |  |  |  |  |  |  |  |  | $ 435,000,000 |  |  |  |
Potential commercial milestone payments under agreement |  |  |  |  |  |  |  |  | $ 330,000,000 |  |  |  |
Development and regulatory milestones recognized |  |  |  |  | 15,000,000 |  |  |  |  | 70,000,000 |  |  |
Number of performance obligations | performanceObligation |  |  |  |  |  |  |  |  | 2 |  |  |  |
Collaborative agreement transaction price |  |  |  |  |  |  |  |  | $ 154,000,000 |  |  |  |
Variable consideration recognized |  |  |  |  |  |  |  |  | $ 4,000,000 |  |  |  |
Incyte Corporation | Incyte MGA012 Agreement | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Two Additional Incyte License Agreement Milestone |  |  |  |  |  |  |  |  |  |  | $ 30,000,000 |  |
I-Mab | I-Mab Biopharma Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |
Potential development and regulatory milestone payments under agreement |  |  |  |  |  |  |  |  |  |  |  |  | $ 135,000,000
Development and regulatory milestones recognized |  | $ 5,000,000 |  | 5,000,000 |  |  |  |  |  |  |  |  |
Revenues | 600,000 |  | 1,900,000 | 700,000 | 2,500,000 |  |  |  |  |  |  |  |
Deferred revenue | 3,800,000 |  |  | 3,800,000 |  |  |  |  |  | 3,800,000 |  | $ 4,500,000 |
Minimum | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from royalties (percent) |  |  |  |  |  |  |  | 15.00% |  |  |  |  |
Maximum | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from royalties (percent) |  |  |  |  |  |  |  | 24.00% |  |  |  |  |
Maximum | I-Mab | I-Mab Biopharma Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from royalties (percent) |  |  |  |  |  |  | 20.00% |  |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | 0 |  | 5,000,000 | 0 |  |  |  |  |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | 200,000 |  | 700,000 | 500,000 | 800,000 |  |  |  |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | 300,000 |  | $ 2,800,000 | 300,000 | $ 5,900,000 |  |  |  |  |  |  |  |
RevenuesFromCMOAgreementsMember | Incyte Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  | 4,000,000 |  |  |  |  |  |  |  |  |
Deferred revenue | 9,500,000 |  |  | 9,500,000 |  |  |  |  |  | 9,500,000 |  |  |
Deferred revenue, current | 3,300,000 |  |  | 3,300,000 |  |  |  |  |  | 3,300,000 |  |  |
Deferred revenue, net of current portion | 6,200,000 |  |  | 6,200,000 |  |  |  |  |  | 6,200,000 |  |  |
Annual Fixed Payments | $ 14,400,000 |  |  | $ 14,400,000 |  |  |  |  |  | $ 14,400,000 |  |  |
RevenuesFromCMOAgreementsMember | Incyte Corporation | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |

X
- References No definition available. + Details
Name: | mgnx_CollaborativeAgreementTransactionPrice
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development And Regulatory Milestone Payments Under Agreement, Recognized + References No definition available. + Details
Name: | mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | mgnx_NumberOfPerformanceObligations
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_PotentialCommercialMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_ProceedsfromRoyaltiesPercent
Namespace Prefix: | mgnx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount + References No definition available. + Details
Name: | mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total Annual Fixed Payments + References No definition available. + Details
Name: | mgnx_TotalAnnualFixedPayments
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Two Additional Milestone Incyte License Agreement + References No definition available. + Details
Name: | mgnx_TwoAdditionalMilestoneIncyteLicenseAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012SupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |